<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290612</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 00017294</org_study_id>
    <nct_id>NCT03290612</nct_id>
  </id_info>
  <brief_title>Vitamin C to Reduce Morning Cardiovascular Risk</brief_title>
  <official_title>Chronotherapeutic Use of Vitamin C to Reduce Morning Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the efficacy of Vitamin C to counteract morning CV risk markers in a
      randomized, double blind, placebo controlled crossover pilot study. The participants will
      also perform morning typical behaviors such as arousal from sleep, change in posture (getting
      out of bed) and mild intensity physical activity; identical to the stressors encountered in
      everyday life. Primary dependent variables are markers of cardiovascular risk including
      vascular endothelial function and oxidative stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators plan to test the efficacy of Vitamin C to counteract morning CV risk
      markers in a randomized, double blind, placebo controlled crossover pilot study. The
      participants will also perform morning typical behaviors such as arousal from sleep, change
      in posture (getting out of bed) and mild intensity physical activity; identical to the
      stressors encountered in everyday life. This pilot study is in healthy middle aged adults
      without a history of CV disease.

      Participants will spend two nights in an inpatient hospital suite at Hatfield Research
      Center. Upon awakening in the morning, they will either ingest Vitamin C or placebo in a
      randomized order. This will be followed by moderate intensity exercise, recovery, and
      discharge.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Vitamin C and Placebo doses will be blinded by the research pharmacy, so that participants and investigators are masked to the identity of the tablet. Data analysis will be blinded to the conditions as well until the completion of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular Endothelial Function</measure>
    <time_frame>Over two 2-day stays.</time_frame>
    <description>Vascular endothelial function will be measured as FMD. We will measure FMD immediately upon awakening in a constant posture following an overnight fast using the standard guidelines and protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Over two 2-day stays.</time_frame>
    <description>We will quantify oxidative stress in plasma (i.e. ELISA for malondialdehyde (MDA) adduct).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Vitamin C and Tetrahydrobiopterin</measure>
    <time_frame>Over two 2-day stays.</time_frame>
    <description>We will measure Vitamin C levels in the plasma to ensure that the levels are increased after supplementation, and to control for baseline levels. We will measure BH4 from the plasma to test if levels are increased upon administration of Vitamin C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>Over two 2-day stays.</time_frame>
    <description>Platelet aggregation will be measured using Chronolog 560 VS Platelet aggregometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen activator inhibitor -1</measure>
    <time_frame>Over two 2-day stays.</time_frame>
    <description>We will measure PAI-1 in the plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Vitamin C then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>1.5g Ascorbic Acid</description>
    <arm_group_label>Vitamin C then Placebo</arm_group_label>
    <arm_group_label>Placebo then Vitamin C</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive placebo to mimic 1.5g ascorbic acid.</description>
    <arm_group_label>Vitamin C then Placebo</arm_group_label>
    <arm_group_label>Placebo then Vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants

          -  Normal weight or overweight but not obese (18.5&lt;BMI&lt;30 kg/m2)

        Exclusion Criteria:

          -  History of smoking/tobacco use

          -  Current prescription/non-prescription medications or drugs of abuse

          -  Acute, chronic, or debilitating medical conditions

          -  History of working irregular day and night hours, regular night work, or rotating
             shift work for the six months prior to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Saurabh S Thosar, PhD</last_name>
    <phone>5034942064</phone>
    <email>thosar@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya Herzig, BA</last_name>
    <phone>5034942509</phone>
    <email>herzig@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh S Thosar, PhD</last_name>
      <phone>503-494-2064</phone>
      <email>thosar@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Steven A. Shea</investigator_full_name>
    <investigator_title>Director, Oregon Institute of Occupational Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Sleep</keyword>
  <keyword>Vitamin C</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

